Treatment of the jaundiced patient with breast carcinoma: Case report and alternate therapeutic strategies

Cancer

Volumn 91, Issue 4, 2001, Pages 660-663

  Gurevich, Irina ^a   Akerley, Wallace ^b,c  

^a BROWN UNIVERSITY   (United States)

^b BOSTON UNIVERSITY   (United States)

^c BOSTON MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Doxorubicin; Hyperbilirubinemia; Liver; Metastasis

Indexed keywords

BILIRUBIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PACLITAXEL; TAMOXIFEN;

ADULT; ARTICLE; BLOOD TOXICITY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CASE REPORT; DOSE CALCULATION; DRUG CLEARANCE; DRUG CONTRAINDICATION; FEMALE; HUMAN; HYPERBILIRUBINEMIA; JAUNDICE; LIVER METASTASIS; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROGNOSIS; TREATMENT FAILURE;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; JAUNDICE; LIVER NEOPLASMS; MIDDLE AGED; TREATMENT FAILURE;

EID: 0035864840     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20010215)91:4<660::AID-CNCR1048>3.0.CO;2-3     Document Type: Article

References (18)

1. Treatment of patients with liver metastases
2. Breast liver metastases - Incidence, diagnoses and outcome
3. Factors influencing survival in patients with untreated hepatic metastases
4. Clinical course of breast cancer patients with liver metastases
5. Liver metastases: Can our understanding of their biology and prognostic value contribute to a strategy for optimum therapeutic management?
6. Clinical efficacy and toxicity of standard dose Adriamycin in hyperbilirubinemic patients with hepatocellular carcinoma: Relation to liver tests and pharmacokinetic parameters
7. Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264
8. Pharmacokinetics of vinorelbine in patients with liver metastases
9. Use of the automatic interaction detector method to identify patient characteristics related to methotrexate clearance
10. Pharmacokinetics of anticancer agents in patients with impaired liver function
11. Xeloda in the treatment of metastatic breast cancer
12. Effect of hepatic dysfunction due to liver metastases on the pharmacokinetics of capecitabine and its metabolites
13. Effect of liver failure on the pharmacokinetics of cyclophosphamide
14. Phase I trial of weekly paclitaxel in advanced lung cancer
15. Adriamycin chemotherapy- efficacy, safety, and pharmacologic basis of an intermittent single high-dose schedule
16. Weekly epirubicin for breast cancer with liver metastases and abnormal liver biochemistry